A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
-
Published:2021-05-10
Issue:10
Volume:77
Page:1473-1484
-
ISSN:0031-6970
-
Container-title:European Journal of Clinical Pharmacology
-
language:en
-
Short-container-title:Eur J Clin Pharmacol
Author:
Zeitlinger Markus, Bauer Martin, Reindl-Schwaighofer Roman, Stoekenbroek Robert M., Lambert Gilles, Berger-Sieczkowski Evelyn, Lagler Heimo, Oesterreicher Zoe, Wulkersdorfer Beatrix, Lührs Petra, Galabova Gergana, Schwenke Carsten, Mader Robert M., Medori Rossella, Landlinger Christine, Kutzelnigg Alexandra, Staffler GüntherORCID
Abstract
Abstract
Purpose
AT04A and AT06A are two AFFITOPE® peptide vaccine candidates being developed for the treatment of hypercholesterolemia by inducing proprotein convertase subtilisin/kexin type 9 (PCSK9)-specific antibodies. This study aimed to investigate safety, tolerability, antibody development, and reduction of low-density lipoprotein cholesterol (LDLc) following four subcutaneous immunizations.
Methods
This phase I, single-blind, randomized, placebo-controlled study was conducted in a total of 72 healthy subjects with a mean fasting LDLc level at baseline of 117.1 mg/dL (range 77–196 mg/dL). Each cohort enrolled 24 subjects to receive three priming immunizations at weeks 0, 4, and 8 and to receive a single booster immunization at week 60 of either AT04A, AT06A, or placebo. In addition to safety (primary objective), the antigenic peptide- and PCSK9-specific antibody response and the impact on LDLc were evaluated over a period of 90 weeks.
Results
The most common systemic treatment-related adverse events (AEs) reported were fatigue, headache, and myalgia in 75% of subjects in the AT06A group and 58% and 46% of subjects in the placebo and AT04A groups, respectively. Injection site reactions (ISR) representing 63% of all treatment-emergent adverse events (TEAEs), were transient and mostly of mild or moderate intensity and rarely severe (3%). Both active treatments triggered a robust, long-lasting antibody response towards the antigenic peptides used for immunization that optimally cross-reacted with the target epitope on PCSK9. In the AT04A group, a reduction in serum LDLc was observed with a mean peak reduction of 11.2% and 13.3% from baseline compared to placebo at week 20 and 70 respectively, and over the whole study period, the mean LDLc reduction for the AT04A group vs. placebo was −7.2% (95% CI [−10.4 to −3.9], P < 0.0001). In this group, PCSK9 target epitope titers above 50 were associated with clinically relevant LDLc reductions with an individual maximal decrease of 39%.
Conclusions
Although both AT04A and AT06 were safe and immunogenic, only AT04A demonstrated significant LDLc-lowering activity, justifying further development.
Trial registration
EudraCT: 2015-001719-11. ClinicalTrials.gov
Identifier: NCT02508896.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference26 articles.
1. Organization WH (2018) Fact sheets cardiovascular diseases 2. Shin S, Park HB, Chang HJ, Arsanjani R, Min JK, Kim YJ, Lee BK, Choi JH, Hong GR, Chung N (2017) Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study. JACC Cardiovasc Imaging 10:437–446. https://doi.org/10.1016/j.jcmg.2016.04.013 3. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L, Tokgozoglu L, Wood D, De Bacquer D, collaborators EV, Writing C, Scientific Steering/ Executive C, Coordinating C, Diabetes C, Data management c, Statistical analysis c, Central l, Study centres oi, other research p (2019) Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 285, 2019:135-146. https://doi.org/10.1016/j.atherosclerosis.2019.03.014 4. Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385:1397–1405. https://doi.org/10.1016/S0140-6736(14)61368-4 5. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–2561. https://doi.org/10.1016/S0140-6736(16)31357-5
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|